Objective: To understand the changing trajectory of quality of life(QOL) during the treatment courses of breast cancer patients during chemotherapy and to investigate the factors in each treatment course that affec...Objective: To understand the changing trajectory of quality of life(QOL) during the treatment courses of breast cancer patients during chemotherapy and to investigate the factors in each treatment course that affect QOL.Methods: The M.D. Anderson Symptom Inventory Scale, the Hospital Anxiety and Depression Scale(HADS), and the Functional Assessment of Cancer Therapy-Breast(FACT-B) scale were used to perform a survey on 174 breast cancer patients who received the TAC(docetaxel, Adriamycin, and cyclophosphamide) chemotherapy regimen before postoperative chemotherapy and 5-7 days after each chemotherapy course.Results: The QOL scores of the breast cancer patients were the lowest before the postoperative chemotherapy(81.2 ± 19.6) and the highest after the second chemotherapy course(94.5 ± 14.4). After the fourth and fifth chemotherapy courses, the scores were much lower again, with values of 82.7 ± 13.9and 82.6 ± 13.1, respectively. The scores improved again after the sixth chemotherapy course(93.9 ± 18.7). Furthermore, each treatment course had different related symptoms that affected the QOL of the patients.Conclusions: More attention should be paid to the changing trajectory of QOL of patients in all treatment courses and to the influence of treatment-related symptoms on the QOL of patients; moreover, interventions should be adopted by medical care personnel to increase QOL in cancer patients.展开更多
This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor(ER), proges...This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor(ER), progesterone receptor(PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry.Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2%(79/521), 26.9%(140/520) and 44.8%(225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5%(39/521), 13.3%(69/520) and 21.1%(106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7%(40/521), 13.6%(71/520)and 23.7%(119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.展开更多
基金supported by a project of scientific research of the Affiliated Hospital of Luzhou Medical College(No.14039)
文摘Objective: To understand the changing trajectory of quality of life(QOL) during the treatment courses of breast cancer patients during chemotherapy and to investigate the factors in each treatment course that affect QOL.Methods: The M.D. Anderson Symptom Inventory Scale, the Hospital Anxiety and Depression Scale(HADS), and the Functional Assessment of Cancer Therapy-Breast(FACT-B) scale were used to perform a survey on 174 breast cancer patients who received the TAC(docetaxel, Adriamycin, and cyclophosphamide) chemotherapy regimen before postoperative chemotherapy and 5-7 days after each chemotherapy course.Results: The QOL scores of the breast cancer patients were the lowest before the postoperative chemotherapy(81.2 ± 19.6) and the highest after the second chemotherapy course(94.5 ± 14.4). After the fourth and fifth chemotherapy courses, the scores were much lower again, with values of 82.7 ± 13.9and 82.6 ± 13.1, respectively. The scores improved again after the sixth chemotherapy course(93.9 ± 18.7). Furthermore, each treatment course had different related symptoms that affected the QOL of the patients.Conclusions: More attention should be paid to the changing trajectory of QOL of patients in all treatment courses and to the influence of treatment-related symptoms on the QOL of patients; moreover, interventions should be adopted by medical care personnel to increase QOL in cancer patients.
基金supported by National Natural Science Foundation of China (NSFC) (81372851)
文摘This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor(ER), progesterone receptor(PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry.Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2%(79/521), 26.9%(140/520) and 44.8%(225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5%(39/521), 13.3%(69/520) and 21.1%(106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7%(40/521), 13.6%(71/520)and 23.7%(119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.